Abstract
The binding mode analysis of Gefitinib revealed that 6-propylmorpholino group (sidechain) shows no interactions due to its weak electron density. In order to modify the electron density of Gefitinib’s sidechain, novel pyrrolidino analogs of Gefitinib where morpholino groups were replaced by substituted pyrrolidino groups were synthesized. Gefitinib derivatives with high electronegativity atoms or groups in the pyrrolidino moiety always exhibit high potent activity against EGFR and human cancer cell lines, A431, MDA-MB-231 and A549. Among these derivatives, 16 displayed the best pharmacokinetic properties that make it to be a promising candidate for developing drugs to replace Gefitinib.
Keywords: Gefitinib, anticancer, EGFR, pyrrolidino analogue, pharmacokinetic property.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties
Volume: 16 Issue: 12
Author(s): Jing-Kun Fang, Zhimin Xu, Yingjun Zhang, Weihong Zhang, Bing Liu, Yu Fang and Tengxiao Sun
Affiliation:
Keywords: Gefitinib, anticancer, EGFR, pyrrolidino analogue, pharmacokinetic property.
Abstract: The binding mode analysis of Gefitinib revealed that 6-propylmorpholino group (sidechain) shows no interactions due to its weak electron density. In order to modify the electron density of Gefitinib’s sidechain, novel pyrrolidino analogs of Gefitinib where morpholino groups were replaced by substituted pyrrolidino groups were synthesized. Gefitinib derivatives with high electronegativity atoms or groups in the pyrrolidino moiety always exhibit high potent activity against EGFR and human cancer cell lines, A431, MDA-MB-231 and A549. Among these derivatives, 16 displayed the best pharmacokinetic properties that make it to be a promising candidate for developing drugs to replace Gefitinib.
Export Options
About this article
Cite this article as:
Fang Jing-Kun, Xu Zhimin, Zhang Yingjun, Zhang Weihong, Liu Bing, Fang Yu and Sun Tengxiao, Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (12) . https://dx.doi.org/10.2174/1871520616666160622094153
DOI https://dx.doi.org/10.2174/1871520616666160622094153 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Single-Cell Sequencing for Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Current Cancer Therapy Reviews Enjoy the Silence: The Story of let-7 MicroRNA and Cancer
Current Genomics Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters
Current Drug Delivery Discovery of Cationic Polymers for Non-Viral Gene Delivery Using Combinatorial Approaches
Combinatorial Chemistry & High Throughput Screening Medical Treatment of Gastrointestinal Stromal Tumors: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Current Pharmaceutical Design Genetics of Preneoplasia: Lessons from Lung Cancer
Current Molecular Medicine Multiple Forms of Human DNA Polymerase Delta Sub-Assembling in Cellular DNA Transactions
Current Protein & Peptide Science Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Synthesis and In-Vitro Antitumor Activity of Selected 7-Fluoro-6-(4-methyl-1-piperazinyl)-2-(thiosubstituted)-4(3H)-quinazolinones
Letters in Organic Chemistry Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Advances and Perspectives in Cell-Specific Aptamers
Current Pharmaceutical Design Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review
Current Drug Metabolism Genetic Manipulation of Human Embryonic Stem Cells: A System to Study Early Human Development and Potential Therapeutic Applications
Current Gene Therapy